Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME of Tucatinib in Healthy Subjects
NCT03758339Phase 1Completed
- Sponsor
- Cascadian Therapeutics
- Start
- Dec 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tucatinib in HER2-positive breast cancer, sponsored by Cascadian Therapeutics. Primary endpoints: Area under the concentration-time curve (AUC) from time 0 to infinity up to 14 days, AUC from time 0 to last quantifiable concentration up to 14 days and 9 more. Started Dec 2017; status: completed.
02
Drugs
tucatinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT03758339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03758339.